Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Telix Pharmaceuticals Limited for possible violations of federal securities laws and unlawful business practices [1][2]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Telix to contact them to discuss their legal rights [1]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates [2]. - Following the subpoena news, Telix's American Depositary Receipt (ADR) price dropped by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [2]. Group 2: Contact Information - Investors can reach out to Bragar Eagel & Squire for more information about the claims or their rights without any cost or obligation [3]. - Contact details for the law firm include phone number (212) 355-4648 and email investigations@bespc.com [6].
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm